Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients With Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial

What this Trial Is About

Pseudomonas aeruginosa is a harmful bacteria, especially in hospital environments, that can become resistant to many or all antibiotics commonly used to treat it. Researchers aim to isolate and produce therapeutic antibodies against Pseudomonas aeruginosa to provide an alternative treatment option for infections caused by antibiotic-resistant strains. This study is observational and focuses on patients who have been monitored for infection or colonization with this bacteria. The study involves isolating anti-Pseudomonas antibodies from type B lymphocytes through blood sampling. Mononuclear cells are separated from the blood using density gradient centrifugation, and functional antibodies are identified using ELISA and cellular infection tests. This process allows researchers to study the therapeutic potential of these antibodies without administering treatments to participants. Participants will provide blood samples during follow-up visits at Grenoble University Hospital as part of their care. The main outcome measured is the successful isolation of recombinant human monoclonal antibodies against Pseudomonas aeruginosa. Secondary outcomes include identifying functional antibodies. The study involves no additional treatments, and participation is monitored through standard blood sampling procedures. The total study duration extends until October 2026.

Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies